# Tesamorelin withdrawal findings

> Tesamorelin — Sponsored Trials Evidence Review — Tesamorelin in Sponsored Trials Evidence Review: HIV-associated visceral fat, the return after stopping treatment, scan findings and growth-hormone cautions.

**Follow-up**

The return of fat after treatment changes the bargain. I want that follow-up included whenever a reduction in visceral fat is reported.

## Fat returning after withdrawal

In the [52-week tesamorelin program](https://pubmed.ncbi.nlm.nih.gov/18690162/), continued treatment sustained a reduction in visceral fat, the fat around internal organs. Fat reaccumulated when treatment stopped. The participants were adults with HIV-associated abdominal fat accumulation.

I regard that return as one of the study’s most useful findings. It changes the practical question from whether fat can be reduced to how a benefit is maintained, for whom and with what continuing burden. A final visit during treatment would leave that question hanging.

[Tesamorelin’s FDA-approved purpose](https://www.ncbi.nlm.nih.gov/books/NBK548730/) is reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Approval covers that specific condition. The evidence here does not establish an ordinary weight-loss or anti-aging treatment for the general population.

## Fat measured on a scan

A [six-month randomized trial in 50 adults with HIV receiving antiretroviral treatment](https://pubmed.ncbi.nlm.nih.gov/25038357/) reported a visceral-fat treatment effect of −42 square centimeters. That is the difference in change between the tesamorelin and placebo groups. A scan measures the area in an abdominal slice; kilograms on a scale measure something else. Liver fat also fell in that trial.

The [meta-analysis of five randomized trials](https://pubmed.ncbi.nlm.nih.gov/41545261/) found a mean visceral-fat difference of −27.71 square centimeters, with reductions in trunk and liver fat and an increase in lean body mass. Lean body mass includes water and other tissues as well as muscle; I hesitate to describe that whole gain as muscle.

The HIV-associated condition remains in the result every time those figures travel. Replacing it with a general claim about belly fat removes the very population that supplied the evidence.

![A technician prepares an empty magnetic resonance scanner in a cream and lavender room](images/imaging-preparation.webp)

*An imagined research-imaging room. Abdominal imaging can locate changes that a weighing scale cannot; this scene depicts no participant or named facility.*

## Hormone stimulation: safety findings

Tesamorelin prompts the pituitary gland to release growth hormone in pulses. The liver then produces more IGF-1, a growth factor. The [short study of 13 healthy men](https://pubmed.ncbi.nlm.nih.gov/20943777/) found increased growth hormone and IGF-1 over two weeks, without a clear change in fasting glucose or insulin-stimulated glucose uptake. Its brief duration leaves long-term safety open.

Growth-hormone stimulation makes the safety questions substantial. Active cancer is a contraindication to the approved medicine. Years of elevated IGF-1 and changes in blood sugar require attention; the trials cannot settle every uncommon or late harm. Tesamorelin is also prohibited in sport because of its growth-hormone action.

The [NIH LiverTox assessment](https://www.ncbi.nlm.nih.gov/books/NBK548730/) regards clinically apparent liver injury from tesamorelin as unlikely. The combined trial review found no recurring pattern of serious harms attributed to the treatment. I welcome that reassurance within its observation period, while leaving rare events and longer exposure on the agenda.

This is a different proposition from [semaglutide’s serious-illness trials](/semaglutide). The fat findings answer a particular question in adults living with HIV, and the return after withdrawal deserves a place beside the reduction.

---

An independent peptide-trial briefing that audits sponsor roles and published evidence, never a clinic, placement service, or source of medical advice.